EVISTA NORDIC FUSION
| Features | |
| Also known as | Raloxifene hydrochloride |
| Blood pressure | Typically has no significant effect on blood pressure |
| Chemical name | [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride |
| Dosage (medical) | Commonly prescribed as 60 mg per day |
| Dosage (sports) | Not typically used in sports for performance enhancement |
| Effects | Reduces the risk of osteoporosis, decreases total and LDL cholesterol |
| Formula | C28H27NO4SВ·HCl |
| Half-life | Approximately 27.7 hours |
| Hepatotoxicity | Low risk |
| Lab Test | Not specific, general liver function tests may be monitored |
| Main action | Estrogen receptor modulator |
| Raw Material | Raloxifene Hydrochloride |
| Side effects | Hot flashes, leg cramps, increased risk of venous thromboembolism, stroke |
| Storage conditions | Store at room temperature, protect from moisture and heat |
| Substance class | Selective Estrogen Receptor Modulator (SERM) |
| Trade name | Evista |
| Use in sports | None, as it is not known for performance enhancement |
| Water Retention | None |
| Manufacturer | NORDIC FUSION |
| Packing | 50 tabs (30 mg/tab) |